Leslie Lauersdorf addresses the different questions her patients ask her when they begin daratumumab therapy.
Leslie Lauersdorf explains why it's so important to understand the patient's baseline to help manage side effects.
Leslie Lauersdorf has seen the Janssen CarePath Program help alleviate some of the financial burden of treatment for her patients.
Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.
An early access study confirms the safety and preservation of health-related quality of life of daratumumab in multiple myeloma.
Combinations of targeted agents that include daratumumab offer synergy to alter the tumor microenvironment to promote the efficacy of these combinations in the treatment of multiple myeloma.
PREAMBLE is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with 1 line of prior therapy.
A leading cancer clinic has developed an innovative response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.
Preliminary data suggest that subcutaneous delivery of daratumumab in patients with relapsed/refractory multiple myeloma is well-tolerated and yields similar response rates to intravenous administration of the drug.
Page 11 of 16
Results 101 - 110 of 159